국내 HIV 감염인의 HIV/AIDS 진단 및 치료에 관한 임상진료지침 권고안

키워드

참고문헌 (265)

1. Aberg JA, "Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.651~681 (2009)
2. Kaplan JE, "Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America", MMWR Recomm Rep, 58, pp.1~207 (2009)
3. Clumeck N, "European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults", HIV Med, 9, pp.65~71 (2008)
4. "Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents"[URL]
5. Mellors JW, "Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection", Ann Intern Med, 126, pp.946~954 (1997)
6. Egger M, "Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies", Lancet, 360, pp.119~129 (2002)
7. Hughes MD, "Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team", Ann Intern Med, 126, pp.929~938 (1997)
8. Marschner IC, "Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy", J Infect Dis, 177, pp.40~47 (1998)
9. Thiébaut R, "Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA)", AIDS, 14, pp.971~978 (2000)
10. Freedberg KA, "Initial assessment of patients infected with human immunodeficiency virus: the yield and cost of laboratory testing", J Acquir Immune Defic Syndr, 7, pp.1134~1140 (1994)
11. Samaras K, "Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy", J Acquir Immune Defic Syndr, 50, pp.499~505 (2009)
12. Antinori A, "Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy", Infection, 37, pp.270~282 (2009)
13. Gandhi RT, "Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies", J Infect Dis, 191, pp.1435~1441 (2005)
14. Schwarcz S, "Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS", J Acquir Immune Defic Syndr, 43, pp.491~494 (2006)
15. Battegay M, "Late presentation of HIV-infected individuals", Antivir Ther, 12, pp.841~851 (2007)
16. Palella FJ Jr, "HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study", J Acquir Immune Defic Syndr, 43, pp.27~34 (2006)
17. Mallal S, "HLA-B*5701 screening for hypersensitivity to abacavir", N Engl J Med, 358, pp.568~579 (2008)
18. Park WB, "Should HLA-B*5701 Screening Be Performed in Every Ethnic Group before Starting Abacavir?", CLINICAL INFECTIOUS DISEASES, 48, pp.365~367 (2009), UNIV CHICAGO PRESS
19. Saag M, "High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients", Clin Infect Dis, 46, pp.1111~1118 (2008)
20. Hammer SM, "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel", JAMA, 296, pp.827~843 (2006)
21. Bang JI, "Prevalence of primary antiretroviral resistance: Trends in Korea", AIDS RESEARCH AND HUMAN RETROVIRUSES, 24, pp.83~85 (2008), 미국
22. 송준영, "치료 경험이 없는 HIV 감염자에서의 항바이러스제 일차 내성 분석: 한국HIV", AIDS 코호트 연구, 2009, pp.41(4), 230~232[DOI]
23. 김서린, "치료력이 없는 HIV 감염환자에서 약제내성 빈도", 대한내과학회지, 73(3), pp.243~250 (2007), 대한내과학회
24. De Santis M, "Hemangiomas and other congenital malformations in infants exposed to antiretroviral therapy in utero", JAMA, 291, pp.305~ (2004)
25. Fundarò C, "Myelomeningocele in a child with intrauterine exposure to efavirenz", AIDS, 16, pp.299~300 (2002)
26. Ledergerber B, "AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study", JAMA, 282, pp.2220~2226 (1999)
27. Smit C, "Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion", AIDS, 20, pp.741~749 (2006)
28. d'Arminio Monforte A, "The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy", Arch Intern Med, 165, pp.416~423 (2005)
29. Nunn P, "Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality", Am Rev Respir Dis, 146, pp.849~854 (1992)
30. Verhofstede C, "Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype", AIDS, 13, pp.2541~2546 (1999)
31. Miller V, "Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure", AIDS, 14, pp.2857~2867 (2000)
32. Devereux HL, "Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy", AIDS, 13, pp.123~127 (1999)
33. Grulich AE, "Incidence of cancers in people with HIV", AIDS compared with immunosuppressed transplant recipients: a meta-analysis, 2007, pp.370, 59~67
34. Long JL, "Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals", AIDS, 22, pp.489~496 (2008)
35. Patel P, "Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003", Ann Intern Med, 148, pp.728~736 (2008)
36. DAD Study Group, "Class of antiretroviral drugs and the risk of myocardial infarction", N Engl J Med, 356, pp.1723~1735 (2007)
37. Weber R, "Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study", Arch Intern Med, 166, pp.1632~1641 (2006)
38. Gupta SK, "Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 40, pp.1559~1585 (2005)
39. Choi AI, "Racial differences in end-stage renal disease rates in HIV infection versus diabetes", J Am Soc Nephrol, 18, pp.2968~2974 (2007)
40. Mocroft A, "Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group", Lancet, 352, pp.725~730 (1998)
41. Hogg RS, "Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy", JAMA, 286, pp.2568~2877 (2001)
42. Palella FJ Jr, "Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata", Ann Intern Med, 138, pp.620~626 (2003)
43. Baker JV, "CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection", AIDS, 22, pp.841~848 (2008)
44. Sterne JA, "Timing of initiation of antiretroviral therapy in AIDS-free HIV-1- infected patients: a collaborative analysis of 18 HIV cohort studies", Lancet, 373, pp.1352~1363 (2009)
45. Severe P, "A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected with a CD4 T cell count of 200-350 cells", μL (CIPRA HT001), 2009, ~
46. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, "Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study", J Infect Dis, 197, pp.1133~1144 (2008)
47. Lodwick R, "Age-and sex-specific death rates in ART-naïve patients with CD4 count above 350 cells", mm3 compared with the general population, 2008, ~
48. Lewden C, "Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. HIV-infected adults with a CD4 cell count greater than 500 cells", mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population, 2007, pp.46, 72~77
49. Thein HH, "Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a metaanalysis", AIDS, 22, pp.1979~1991 (2008)
50. Thio CL, "Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)", Lancet, 360, pp.1921~1926 (2002)
51. Macías J, "Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus", hepatitis C virus, 2009, pp.50, 1056~1063
52. Verma S, "Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis", BMC Res Notes, 1, pp.46~ (2008)
53. Ragni MV, "Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection", Haemophilia, 15, pp.552~558 (2009)
54. Avidan NU, "Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV", HCV coinfected patients as a function of baseline CD4+ T-cell counts, 2009, pp.52, 452~458
55. Clotet B, "Efficacy and safety of darunavir-ritonavir at week 48 in treatmentexperienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials", Lancet, 369, pp.1169~1178 (2007)
56. Hammer SM, "Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel", JAMA, 300, pp.555~570 (2008)
57. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, "Response to combination antiretroviral therapy: variation by age", AIDS, 22, pp.1463~1473 (2008)
58. Nogueras M, "Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more", BMC Infect Dis, 6, pp.159~ (2006)
59. Bosch RJ, "Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy", J Acquir Immune Defic Syndr, 44, pp.268~277 (2007)
60. D:A:D Study Group, "Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration", Lancet, 371, pp.1417~1426 (2008)
61. Ross AC, "Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy", J Acquir Immune Defic Syndr, 49, pp.499~506 (2008)
62. Baker JV, "Untreated HIV infection and large and small artery elasticity", J Acquir Immune Defic Syndr, 52, pp.25~31 (2009)
63. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, "CD4+ count-guided interruption of antiretroviral treatment", N Engl J Med, 355, pp.2283~2296 (2006)
64. Torriani FJ, "Endothelial function in human immunodeficiency virus-infected antiretroviral- naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s", J Am Coll Cardiol, 52, pp.569~576 (2008)
65. Marin B, "Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy", AIDS, 23, pp.1743~1753 (2009)
66. Bedimo RJ, "Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression", J Acquir Immune Defic Syndr, 52, pp.203~208 (2009)
67. Guiguet M, "Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): a prospective cohort study", Lancet Oncol, 10, pp.1152~1159 (2009)
68. Monforte A, "HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies", AIDS, 22, pp.2143~2153 (2008)
69. Bruyand M, "Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort", Clin Infect Dis, 49, pp.1109~1116 (2009)
70. Silverberg MJ, "HIV infection and the risk of cancers with and without a known infectious cause", AIDS, 23, pp.2337~2345 (2009)
71. Zoufaly A, "Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma", J Infect Dis, 200, pp.79~87 (2009)
72. May M, "Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies", AIDS, 21, pp.1185~1197 (2007)
73. Kitahata MM, "Effect of early versus deferred antiretroviral therapy for HIV on survival", N Engl J Med, 360, pp.1815~1826 (2009)
74. HIV-CAUSAL Collaboration, "The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals", AIDS, 24, pp.123~137 (2010)
75. Bhaskaran K, "Changes in the risk of death after HIV seroconversion compared with mortality in the general population", JAMA, 300, pp.51~59 (2008)
76. Ferry T, "Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO", COPILOTE (ANRS CO8) cohort study, 2009, pp.51, 407~415
77. Hargrove JW, "Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe", AIDS, 24, pp.F11~F14 (2010)
78. "Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions in the United states-April 29, 2009"[URL]
79. "European guidelines for clinical management and treatment of HIV infected adults in Europe"[URL]
80. Szczech LA, "The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection", Kidney Int, 66, pp.1145~1152 (2004)
81. Marras D, "Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy", Nat Med, 8, pp.522~526 (2002)
82. Estrella M, "HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients", Clin Infect Dis, 43, pp.377~380 (2006)
83. Atta MG, "Antiretroviral therapy in the treatment of HIV-associated nephropathy", Nephrol Dial Transplant, 21, pp.2809~2813 (2006)
84. Schwartz EJ, "Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease", J Am Soc Nephrol, 16, pp.2412~2420 (2005)
85. Kalayjian RC, "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease", AIDS, 22, pp.481~487 (2008)
86. Matthews GV, "A randomized trial of combination hepatitis B therapy in HIV", HBV coinfected antiretroviral naïve individuals in Thailand, 2008, pp.48, 1062~1069
87. Peters MG, "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127", Hepatology, 44, pp.1110~1116 (2006)
88. Mallal S, "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir", Lancet, 359, pp.727~732 (2002)
89. Phillips E, "Genetic characterization of patients with MHC class I mediated abacavir hypersensitivity reaction", Poster session presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention (2007)
90. Sax PE, "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy", N Engl J Med, 361, pp.2230~2240 (2009)
91. Daar E, "ACTG 5202: final results of ABC", 3TC or TDF, r in treatment-naive HIV-infected patients, pp.Poster session presented at: 17th Conference on Retroviruses and Opportunistic Infections, 2010
92. Strategies for Management of Anti-Retroviral Therapy, "INSIGHT", Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients, 2008, pp.22, F17~F24
93. Worm SW, "Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study", J Infect Dis, 201, pp.318~330 (2010)
94. Benson C, "No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001", Poster session presented at: 16th Conference on Retroviruses and Opportunistic Infections (2009)
95. Lang S, "Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a casecontrol study nested within the French Hospital Database on HIV ANRS cohort CO4", Arch Intern Med, 170, pp.1228~1238 (2010)
96. Smith KY, "Randomized, double-blind, placebo-matched, multicenter trial of abacavir", lamivudine or tenofovir, ritonavir for initial HIV treatment, pp.AIDS, 2009[DOI]
97. DeJesus E, "Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral- naive HIV-infected adults", Clin Infect Dis, 39, pp.1038~1046 (2004)
98. Arribas JR, "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine", lamivudine and efavirenz in treatment- naive patients: 144-week analysis, 2008, pp.47, 74~78
99. "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States"[URL]
100. Berenguer J, "Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903", Clin Infect Dis, 47, pp.1083~1092 (2008)
101. Campbell T, "PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs co-formulated zidovudine", lamivudine and efavirenz for initial treatment of HIV-1 infection, 2008, ~
102. Molina JM, "Once-daily atazanavir", ritonavir versus twice-daily lopinavir, Lancet, pp.2008, 372[DOI]
103. Molina JM, "Once-daily atazanavir", ritonavir compared with twice-daily lopinavir, J Acquir Immune Defic Syndr, pp.2010, 53[DOI]
104. McGrath D, "Efficacy and safety by racial group in ARVnaive subjects treated with atazanavir", ritonavir or lopinavir, Poster session presented at: 17th International AIDS Conference, pp.2008[DOI]
105. Riddler SA, "Class-sparing regimens for initial treatment of HIV-1 infection", N Engl J Med, 358, pp.2095~2106 (2008)
106. Haubrich RH, "Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment", AIDS, 23, pp.1109~1118 (2009)
107. Ortiz R, "Efficacy and safety of once-daily darunavir", ritonavir versus lopinavir, AIDS, pp.2008, 22[DOI]
108. Mills AM, "Once-daily darunavir", ritonavir vs. lopinavir, AIDS, pp.2009, 23[DOI]
109. Gathe J, "A oncedaily lopinavir", ritonavir-based regimen is noninferior to twicedaily dosing and results in similar safety and tolerability in antiretroviral- naive subjects through 48 weeks, 2009, pp.50, 474~481
110. Molina JM, "A lopinavir", ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks, 2007, pp.23, 1505~1514
111. Zajdenverg R, "Similar safety and efficacy of once- and twicedaily lopinavir", ritonavir tablets in treatment-experienced HIV-1- infected subjects at 48 weeks, 2010, pp.54, 143~151
112. Cahn P, "Efficacy and safety at 48 weeks of once-daily vs twice-daily DRV", r in treatment-experienced HIV-1+ patients with no DRV resistance associated mutations: the ODIN Trial, 2010, ~
113. "PREZISTA® (darunavir) tablet, film coated for oral use: Full Prescribing Information"[URL]
114. Malan DR, "Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients", J Acquir Immune Defic Syndr, 47, pp.161~167 (2008)
115. Horberg M, "Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients", HIV Clin Trials, 9, pp.367~374 (2008)
116. Santoro MM, "Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study", AIDS Patient Care STDS, 22, pp.7~16 (2008)
117. Lockman S, "Antiretroviral therapies in women after singledose nevirapine exposure", N Engl J Med, 363, pp.1499~1509 (2010)
118. "Sustiva Prescribing Information"[URL]
119. Cooper DA, "Maraviroc versus efavirenz, both in combination with zidovudine- lamivudine, for the treatment of antiretroviralnaive subjects with CCR5-tropic HIV-1 infection", J Infect Dis, 201, pp.803~813 (2010)
120. Lennox JL, "STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz- based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial", Lancet, 374, pp.796~806 (2009)
121. van Leth F, "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study", Lancet, 363, pp.1253~1263 (2004)
122. "Boehringer Ingelheim Pharmaceuticals. ViramuneⓇ Prescribing Information"[URL]
123. Gotuzzo E, "Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment- Naive HIV-1 Infected Patients", Poster session presented at: 17th Conference on Retroviruses and Opportunistic Infections (2010)
124. Young B, "A pilot study of abacavir", lamivudine and raltegravir in antiretroviral-naïve HIV-1 infected subjects: 48 week results, 2008, ~
125. Klein C, "A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects", Poster session presented at: 17th International AIDS Conference (2008)
126. Hirsch M, "A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy", J Infect Dis, 180, pp.659~665 (1999)
127. Gallant JE, "Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects", J Infect Dis, 192, pp.1921~1930 (2005)
128. Bartlett JA, "Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir", Ritonavir, or Stavudine, 2006, pp.43, 284~292
129. Jemsek J, "Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF", Poster session presented at: 11th Conference on Retroviruses and Opportunistic Infections (2004)
130. Puls RL, "Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study", Clin Infect Dis, 51, pp.855~864 (2010)
131. "Reyataz Prescribing Information"[URL]
132. "CrixivanⓇ Prescribing Information"[URL]
133. Moore RD, "Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea", AIDS, 14, pp.273~278 (2000)
134. Robbins GK, "Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection", N Engl J Med, 349, pp.2293~2303 (2003)
135. Boubaker K, "Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study", Clin Infect Dis, 33, pp.1931~1937 (2001)
136. Coghlan ME, "Symptomatic lactic acidosis in hospitalized antiretroviral- treated patients with human immunodeficiency virus infection: a report of 12 cases", Clin Infect Dis, 33, pp.1914~1921 (2001)
137. Anonymous, "Caution issued for HIV combination therapy with Zerit and Videx in pregnant women", HIV Clin, 13, pp.6~ (2001)
138. "IntelenceⓇ Full Prescribing Information"[URL]
139. Bethell R, "Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754", Poster session presented at: 11th Conference on Retroviruses and Opportunistic Infections (2004)
140. Hoggard PG, "Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro", Antimicrob Agents Chemother, 41, pp.1231~1236 (1997)
141. Havlir DV, "In vivo antagonism with zidovudine plus stavudine combination therapy", J Infect Dis, 182, pp.321~325 (2000)
142. Thompson MA, "Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel", JAMA, 304, pp.321~333 (2010)
143. Barbour JD, "Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virusinfected adults", J Virol, 76, pp.11104~11112 (2002)
144. Nettles RE, "Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART", JAMA, 293, pp.817~829 (2005)
145. Lazzarin A, "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia", N Engl J Med, 348, pp.2186~2195 (2003)
146. Cooper DA, "Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection", N Engl J Med, 359, pp.355~365 (2008)
147. Katlama C, "Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials", AIDS, 23, pp.2289~2300 (2009)
148. Gulick RM, "Maraviroc for previously treated patients with R5 HIV-1 infection", N Engl J Med, 359, pp.1429~1441 (2008)
149. Murray JS, "The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs", AIDS, 13, pp.797~804 (1999)
150. Ledergerber B, "Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes", Lancet, 364, pp.51~62 (2004)
151. Raffanti SP, "Effect of persistent moderate viremia on disease progression during HIV therapy", J Acquir Immune Defic Syndr, 37, pp.1147~1154 (2004)
152. Lau B, "Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells", mm3, 2007, pp.44, 179~187
153. Moore RD, "CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression", Clin Infect Dis, 44, pp.441~446 (2007)
154. Kaufmann GR, "CD4 T- lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study", Arch Intern Med, 163, pp.2187~2195 (2003)
155. Tarwater PM, "Increase and plateau of CD4 T-cell counts in the 3(1", 2) years after initiation of potent antiretroviral therapy, 2001, pp.27, 168~175
156. Loutfy MR, "CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy", J Infect Dis, 192, pp.1407~1411 (2005)
157. Ledergerber B, "Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study", Lancet, 353, pp.863~868 (1999)
158. Konopnicki D, "Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort", AIDS, 19, pp.593~601 (2005)
159. Hoffmann CJ, "Hepatitis B and long-term HIV outcomes in coinfected HAART recipients", AIDS, 23, pp.1881~1889 (2009)
160. Dore GJ, "Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption", AIDS, 24, pp.857~865 (2010)
161. Benhamou Y, "Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients", Hepatology, 30, pp.1302~1306 (1999)
162. McMahon MA, "The HBV drug entecavir - effects on HIV-1 replication and resistance", N Engl J Med, 356, pp.2614~2621 (2007)
163. Manegold C, "Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy", Clin Infect Dis, 32, pp.144~148 (2001)
164. Sulkowski MS, "Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection", JAMA, 283, pp.74~80 (2000)
165. den Brinker M, "Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection", AIDS, 14, pp.2895~2902 (2000)
166. Pessôa MG, "Efficacy and safety of entecavir for chronic HBV in HIV", HBV coinfected patients receiving lamivudine as part of antiretroviral therapy, 2008, pp.22, 1779~1787
167. Benhamou Y, "Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an openlabel pilot study", Lancet, 358, pp.718~723 (2001)
168. Ingiliz P, "Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIVinfected patients", Antivir Ther, 13, pp.895~900 (2008)
169. Alter MJ Margolis HS, "The natural history of community-acquired hepatitis C in the United States. The natural history of communityacquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team", N Engl J Med, 327, pp.1899~1905 (1992)
170. Thomas DL, "The natural history of hepatitis C virus infection: host, viral, and environmental factors", JAMA, 284, pp.450~456 (2000)
171. Poynard T, "Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups", Lancet, 349, pp.825~832 (1997)
172. Wiley TE, "Impact of alcohol on the histological and clinical progression of hepatitis C infection", Hepatology, 28, pp.805~809 (1998)
173. Graham CS, "Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis", Clin Infect Dis, 33, pp.562~569 (2001)
174. Sulkowski MS, "Hepatotoxicity associated with nevirapine or efavirenzcontaining antiretroviral therapy: role of hepatitis C and B infections", Hepatology, 35, pp.182~189 (2002)
175. Greub G, "Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study", Lancet, 356, pp.1800~1805 (2002)
176. Vlahov D, "Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count", JAMA, 279, pp.35~40 (1998)
177. Celentano DD, "Self-reported antiretroviral therapy in injection drug users", JAMA, 280, pp.544~546 (1998)
178. Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
179. Soriano V, "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel", AIDS, 21, pp.1073~1089 (2007)
180. Tien PC, "Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office", Am J Gastroenterol, 100, pp.2338~2354 (2005)
181. Avidan NU, "Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV", HCV coinfected patients as a function of baseline CD4+ T-cell counts, 2009, pp.52, 452~458
182. Fleischer R, "Nucleoside analogues and mitochondrial toxicity", Clin Infect Dis, 38, pp.e79~e80 (2004)
183. Alvarez D, "Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons", J Viral Hepat, 13, pp.683~689 (2006)
184. Vispo E, "Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir", Antivir Ther, 13, pp.429~437 (2008)
185. Laufer N, "Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin", Antivir Ther, 13, pp.953~957 (2008)
186. Mira JA, "Efficacy of pegylated interferon plus ribavirin treatment in HIV", hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone, 2008, pp.62, 1365~1373
187. Aranzabal L, "Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection", Clin Infect Dis, 40, pp.588~593 (2005)
188. Labarga P, "Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients", J Infect Dis, 196, pp.670~676 (2007)
189. Núñez M, "Hepatotoxicity of antiretrovirals: incidence, mechanisms and management", J Hepatol, 44(1), pp.S132~S139 (2006)
190. McGovern BH, "Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients", Clin Infect Dis, 43, pp.365~372 (2006)
191. Sulkowski MS, "Hepatitis C in the HIV-infected patient", Clin Liver Dis, 2003, pp.179~194 (2003)
192. Sulkowski MS, "Rapid fibrosis progression among HIV", hepatitis C virus-co-infected adults, 2007, pp.21, 2209~2216
193. Bräu N, "Slower fibrosis progression in HIV", HCV-coinfected patients with successful HIV suppression using antiretroviral therapy, 2006, pp.44, 47~55
194. Macías J, "Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus", hepatitis C virus, 2009, pp.50, 1059~1063
195. Miller MF, "Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis", Clin Infect Dis, 51, pp.713~720 (2005)
196. Kearney M, "Singlegenomesequencing is more sensitive than standard genotype analysis for detection of HIV-1 drug-resistance mutations", Poster session presented at: 11th Conference on Retroviruses and Opportunistic Infections (2004)
197. Hoffmann C, "DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations", Nucleic Acids Res, 35, pp.e91~ (2007)
198. Paredes R, "Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations", J Virol Methods, 146, pp.136~146 (2007)
199. Cai F, "Detection of minor drug-resistant populations by parallel allele-specific sequencing", Nat Methods, 4, pp.123~125 (2007)
200. Devereux HL, "Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy", AIDS, 13, pp.F123~F127 (1999)
201. Kroodsma KL, "Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA", J Infect Dis, 170, pp.1292~1295 (1994)
202. Johnson VA, "Update of the drug resistance mutations in HIV-1: December 2010", Top HIV Med, 18, pp.156~163 (2010)
203. Underwood M, "S", GSK 1349572: a next generation integrase inhibitor with activity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, 2009, ~
204. Seki T, "S", GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones, 2010, ~
205. Goethals O, "Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to firstgeneration integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles", Virology, 402, pp.339~346 (2010)
206. Whitcomb JM, "Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates", J Infect Dis, 188, pp.992~1000 (2003)
207. Lanier ER, "Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens", HIV Med, 5, pp.394~399 (2004)
208. Rhee SY, "Genotypic predictors of human immunodeficiency virus type 1 drug resistance", Proc Natl Acad Sci USA, 103, pp.17355~17360 (2006)
209. Larder BA, "3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors", Antimicrob Agents Chemother, 36, pp.2664~2669 (1992)
210. Whitcomb JM, "Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates", AIDS, 16, pp.F41~F47 (2002)
211. Colonno R, "Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens", J Infect Dis, 189, pp.1802~1810 (2004)
212. Ziermann R, "A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir", J Virol, 74, pp.4414~4419 (2000)
213. Arion D, "Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'- deoxythymidine #AZT#: increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase", Biochemistry, 37, pp.15908~15917 (1998)
214. Deval J, "The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues", J Biol Chem, 277, pp.42097~42104 (2002)
215. Deval J, "Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations", J Biol Chem, 279, pp.509~516 (2004)
216. Sharma PL, "Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val", J Virol, 73, pp.8448~8456 (1999)
217. Cong ME, "The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions", J Virol, 81, pp.3037~3041 (2007)
218. adenine in vitro, "Antimicrob Agents Chemother", 1996, 2212~2216
219. Kosalaraksa P, "Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay", J Virol, 73, pp.5356~5363 (1999)
220. Yoshimura K, "In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues", Antimicrob Agents Chemother, 43, pp.2479~2483 (1999)
221. Larder BA, "Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy", Science, 269, pp.696~699 (1995)
222. Parikh UM, "The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations", J Virol, 80, pp.4971~4977 (2006)
223. Parikh UM, "Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase", AIDS, 21, pp.1405~1414 (2007)
224. Yahi N, "Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences", J Clin Microbiol, 37, pp.4099~4106 (1999)
225. Gonzales MJ, "Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors", AIDS, 17, pp.791~799 (2003)
226. Marcelin AG, "Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure", J Med Virol, 72, pp.162~165 (2004)
227. Miller MD, "Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral- experienced patients", J Infect Dis, 189, pp.837~846 (2004)
228. Cozzi-Lepri A, "Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy", Antivir Ther, 10, pp.791~802 (2005)
229. Riva C, "Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral-naive patients starting highly active antiretroviral therapy", Poster session presented at: 11th International Drug Resistance Workshop (2002)
230. Chappey C, "Evolution of amino acid 215 in HIV-1 reverse transcriptase in response to intermittent drug selection", Poster session presented at: 12th International Drug Resistance Workshop (2003)
231. Violin M, "Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy", AIDS, 18, pp.227~235 (2004)
232. Antinori A, "Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation", Antivir Ther, 12, pp.1175~1183 (2007)
233. Hawkins CA, "Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria", J Acquir Immune Defic Syndr, 52, pp.228~234 (2009)
234. Wallis CL, "Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa", J Acquir Immune Defic Syndr, 53, pp.480~484 (2010)
235. Kozal MJ, "Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy", Ann Intern Med, 121, pp.263~268 (1994)
236. Shafer RW, "Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations", J Infect Dis, 169, pp.722~729 (1994)
237. Harrigan PR, "Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group", J Infect Dis, 181, pp.912~920 (2000)
238. Nicastri E, "Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy", J Med Virol, 69, pp.1~6 (2003)
239. Joly V, "Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1- infected patients switched to antiretroviral therapy without NNRTIs", Antimicrob Agents Chemother, 48, pp.172~175 (2004)
240. Collins JA, "Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants", J Virol, 78, pp.603~611 (2004)
241. Antinori A, "Drugresistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy", AIDS, 15, pp.2325~2327 (2001)
242. Huang W, "Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication", J Virol, 77, pp.1512~1523 (2003)
243. Vingerhoets J, "Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies", AIDS, 24, pp.503~514 (2010)
244. Marcelin AG, "Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor- experienced HIV-1-infected patients", Antimicrob Agents Chemother, 54, pp.72~77 (2010)
245. Witvrouw M, "Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV", AIDS, 13, pp.1477~1483 (1999)
246. Condra JH, "In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors", Nature, 374, pp.569~571 (1995)
247. Kaplan AH, "Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease", Proc Natl Acad Sci USA, 91, pp.5597~5601 (1994)
248. Molla A, "Ordered accumulation of mutations in HIV protease confers resistance to ritonavir", Nat Med, 2, pp.760~766 (1996)
249. Mammano F, "Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug", J Virol, 74, pp.8524~8531 (2000)
250. Prado JG, "Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity", AIDS, 16, pp.1009~1017 (2002)
251. Nijhuis M, "Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy", AIDS, 13, pp.2349~2359 (1999)
252. Menzo S, "Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors", AIDS, 17, pp.663~671 (2003)
253. Devereux HL, "Replicative fitness in vivo of HIV-1 variants with multiple drug resistanceassociated mutations", J Med Virol, 65, pp.218~224 (2001)
254. Maguire MF, "Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro", J Virol, 76, pp.7398~7406 (2002)
255. Maschera B, "Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex", J Biol Chem, 271, pp.33231~33235 (1996)
256. Lataillade M, "Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance", Antivir Ther, 12, pp.563~570 (2007)
257. Hazuda DF, "Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection", Poster session presented at: 16th International Drug Resistance Workshop (2007)
258. Miller MD, "Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005 a phase II study in treatment-experienced patients", Poster session presented at: 17th International Drug Resistance Workshop (2008)
259. Fransen S, "Loss of raltegravir susceptibility in treated patients is conferred by multiple non-overlapping genetic pathways", Poster session presented at: 17th International Drug Resistance Workshop (2008)
260. Hatano H, "Virological and immunological outcomes in a cohort of patients failing integrase inhibitors", Poster session presented at: 17th International Drug Resistance Workshop (2008)
261. Da Silva D, "Mutational patterns in the HIV-1 integrase related to virological failures on raltegravir containing regimens", Poster session presented at: 17th International Drug Resistance Workshop (2008)
262. Ceccherini-Silberstein F, "Virological response and resistance in multi-experienced patients treated with raltegravir", Poster session presented at: 17th International Drug Resistance Workshop (2008)
263. Malet I, "Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro", Antimicrob Agents Chemother, 52, pp.1351~1358 (2008)
264. Geretti AM, "Prevalence and patterns of raltegravir resistance in treated patients in Europe", Poster session presented at: International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies (2010)
265. Hu Z, "Effect of raltegravir resistance mutants in HIV-1 integrase on viral fitness and drug susceptibility", Poster session presented at: 18th International Drug Resistance Workshop (2009)

관련 논문AI추천